Why A Cancer Vaccine is Not a Vaccine

by James Lyons-Weiler, PhD, Popular Rationalism, reposted with permission

(Jan. 22, 2025) — The recent announcement of the Stargate initiative—a $500 billion project led by Oracle, OpenAI, and SoftBank—has ignited global interest. Central to this effort is the development of personalized cancer vaccines, a technology poised to transform medicine. However, the term “vaccine” here is misleading. Cancer vaccines, or better yet, cancer immunotherapies, differ fundamentally from traditional vaccines in purpose, design, and implementation.

This distinction matters because the success of cancer immunotherapies will hinge on their formulation. By prioritizing safety, precision, and transparency, these vaccines could revolutionize cancer treatment and set a new standard for all immunotherapies. Conversely, a failure to focus on formulation could replicate the shortcomings of traditional vaccines, undermining public trust and limiting their potential impact.

While this moment is represented as a pivotal opportunity, cancer immunotherapies could either validate the promise of precision medicine or serve as a cautionary tale about the consequences of neglecting safety.

The Misnomer of “Cancer Vaccine”

Traditional vaccines aim to prevent infectious diseases like measles or polio by training the immune system to recognize and fight specific pathogens. Cancer vaccines, by contrast, are therapeutic—they treat existing diseases rather than prevent them.

Key differences between these two paradigms include:

• Personalization: Cancer immunotherapies are tailored to the unique genetic mutations of an individual’s tumor.
• Dynamic Adaptation: Unlike traditional vaccines, cancer immunotherapies may need to evolve alongside the tumor to remain effective.
• Non-Universal Application: Cancer immunotherapies target a single patient’s tumor, not an entire population.

These differences necessitate a distinct approach to their design, with far greater emphasis on precision and safety.

Why Formulation Matters

The formulation of cancer immunotherapies will determine their success. Unlike traditional vaccines, which often follow a “one-size-fits-all” approach, cancer immunotherapies demand careful consideration of three critical elements:

1. Epitopic Specificity:
   • Cancer immunotherapies must target tumor-specific antigens (TSAs)—mutations or proteins unique to cancer cells. Screening for these antigens is crucial to avoid pathogenic priming, where the immune system learns to mistakenly attack healthy tissues.
   • Traditional vaccines do not undergo this level of scrutiny. For example, molecular mimicry has been implicated in autoimmune reactions like Guillain-Barré syndrome and narcolepsy following vaccination.
2. Adjuvants and Additives:
   • Cancer immunotherapies should prioritize safer adjuvants, such as calcium phosphate, which enhance immune responses without triggering systemic inflammation.
   • Traditional vaccines often rely on aluminum salts or polysorbate 80—ingredients associated with inflammatory responses and long-term health concerns.
3. Delivery Mechanisms:
   • Cutting-edge methods like microneedles or microabrasion could enable localized immune activation, reducing systemic side effects.
   • Traditional intramuscular injections disperse their contents widely, which may amplify the risk of adverse reactions.

Cancer immunotherapies could set a precedent for safer and more effective immunotherapies by focusing on these knowledge-based principles.

Read the rest here.